Loading company…
Mailianco develops next-generation antibody-drug conjugate and dual-target drugs.
Mailianco conducts pharmaceutical research and development, with a pipeline that includes novel-target and dual-target XDC drugs. Founded in 2023 and based in Hangzhou, China, the company received venture funding in November 2025 from Efung Capital and Cowin Asset Management (Shanghai), with Hainan Mailian Technology Partnership (Limited Partnership) and Hangzhou Yuhang Innovation and Development Industry Fund Co., Ltd. also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in